These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

467 related items for PubMed ID: 25369992

  • 1. Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys.
    Kostenuik PJ, Smith SY, Samadfam R, Jolette J, Zhou L, Ominsky MS.
    J Bone Miner Res; 2015 Apr; 30(4):657-69. PubMed ID: 25369992
    [Abstract] [Full Text] [Related]

  • 2. Denosumab treatment is associated with decreased cortical porosity and increased bone density and strength at the proximal humerus of ovariectomized cynomolgus monkeys.
    Haider IT, Sawatsky A, Zhu Y, Page R, Kostenuik PJ, Boyd SK, Edwards WB.
    Bone; 2022 Nov; 164():116517. PubMed ID: 35961611
    [Abstract] [Full Text] [Related]

  • 3. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.
    Ominsky MS, Stouch B, Schroeder J, Pyrah I, Stolina M, Smith SY, Kostenuik PJ.
    Bone; 2011 Aug; 49(2):162-73. PubMed ID: 21497676
    [Abstract] [Full Text] [Related]

  • 4. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody.
    Kostenuik PJ, Smith SY, Jolette J, Schroeder J, Pyrah I, Ominsky MS.
    Bone; 2011 Aug; 49(2):151-61. PubMed ID: 21457806
    [Abstract] [Full Text] [Related]

  • 5. Twelve Months of Denosumab and/or Alendronate Is Associated With Improved Bone Fatigue Life, Microarchitecture, and Density in Ovariectomized Cynomolgus Monkeys.
    Haider IT, Loundagin LL, Sawatsky A, Kostenuik PJ, Boyd SK, Edwards WB.
    J Bone Miner Res; 2023 Mar; 38(3):403-413. PubMed ID: 36533719
    [Abstract] [Full Text] [Related]

  • 6. Sustained Modeling-Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab.
    Ominsky MS, Libanati C, Niu QT, Boyce RW, Kostenuik PJ, Wagman RB, Baron R, Dempster DW.
    J Bone Miner Res; 2015 Jul; 30(7):1280-9. PubMed ID: 25684625
    [Abstract] [Full Text] [Related]

  • 7. Effects of long term treatment with high doses of odanacatib on bone mass, bone strength, and remodeling/modeling in newly ovariectomized monkeys.
    Duong LT, Pickarski M, Cusick T, Chen CM, Zhuo Y, Scott K, Samadfam R, Smith SY, Pennypacker BL.
    Bone; 2016 Jul; 88():113-124. PubMed ID: 27126999
    [Abstract] [Full Text] [Related]

  • 8. Individual and combined effects of exercise and alendronate on bone mass and strength in ovariectomized rats.
    Fuchs RK, Shea M, Durski SL, Winters-Stone KM, Widrick J, Snow CM.
    Bone; 2007 Aug; 41(2):290-6. PubMed ID: 17544352
    [Abstract] [Full Text] [Related]

  • 9. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
    Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG.
    J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
    [Abstract] [Full Text] [Related]

  • 10. Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia.
    Duong LT, Crawford R, Scott K, Winkelmann CT, Wu G, Szczerba P, Gentile MA.
    Bone; 2016 Dec; 93():86-96. PubMed ID: 27639811
    [Abstract] [Full Text] [Related]

  • 11. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.
    Doyle N, Varela A, Haile S, Guldberg R, Kostenuik PJ, Ominsky MS, Smith SY, Hattersley G.
    Osteoporos Int; 2018 Mar; 29(3):685-697. PubMed ID: 29260289
    [Abstract] [Full Text] [Related]

  • 12. Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.
    Pierroz DD, Bonnet N, Baldock PA, Ominsky MS, Stolina M, Kostenuik PJ, Ferrari SL.
    J Biol Chem; 2010 Sep 03; 285(36):28164-73. PubMed ID: 20558734
    [Abstract] [Full Text] [Related]

  • 13. Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength.
    Sakai S, Endo K, Takeda S, Mihara M, Shiraishi A.
    Bone; 2012 May 03; 50(5):1054-63. PubMed ID: 22366400
    [Abstract] [Full Text] [Related]

  • 14. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
    Tutaworn T, Nieves JW, Wang Z, Levin JE, Yoo JE, Lane JM.
    Osteoporos Int; 2023 Mar 03; 34(3):573-584. PubMed ID: 36602607
    [Abstract] [Full Text] [Related]

  • 15. Effects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histomorphometry in ovariectomized rats: a comparison with alfacalcidol and alendronate.
    Sugimoto M, Futaki N, Harada M, Kaku S.
    Bone; 2013 Jan 03; 52(1):181-8. PubMed ID: 23041510
    [Abstract] [Full Text] [Related]

  • 16. Alendronate retards the progression of lumbar intervertebral disc degeneration in ovariectomized rats.
    Luo Y, Zhang L, Wang WY, Hu QF, Song HP, Su YL, Zhang YZ.
    Bone; 2013 Aug 03; 55(2):439-48. PubMed ID: 23500174
    [Abstract] [Full Text] [Related]

  • 17. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
    Li X, Ominsky MS, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Dwyer D, Grisanti M, Stolina M, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ.
    Endocrinology; 2011 Sep 03; 152(9):3312-22. PubMed ID: 21733832
    [Abstract] [Full Text] [Related]

  • 18. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing.
    Gerstenfeld LC, Sacks DJ, Pelis M, Mason ZD, Graves DT, Barrero M, Ominsky MS, Kostenuik PJ, Morgan EF, Einhorn TA.
    J Bone Miner Res; 2009 Feb 03; 24(2):196-208. PubMed ID: 19016594
    [Abstract] [Full Text] [Related]

  • 19. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates.
    Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D.
    J Clin Invest; 1993 Dec 03; 92(6):2577-86. PubMed ID: 8254015
    [Abstract] [Full Text] [Related]

  • 20. Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate.
    Williams DS, McCracken PJ, Purcell M, Pickarski M, Mathers PD, Savitz AT, Szumiloski J, Jayakar RY, Somayajula S, Krause S, Brown K, Winkelmann CT, Scott BB, Cook L, Motzel SL, Hargreaves R, Evelhoch JL, Cabal A, Dardzinski BJ, Hangartner TN, Duong LT.
    Bone; 2013 Oct 03; 56(2):489-96. PubMed ID: 23806798
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.